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Background: Guibi-tang (GBT), a traditional herbal formula, mainly has been shown to possess immune regulation,
antioxidant and protective effect of the gastric mucosa. Constituent herbs of GBT are frequently used to treat
various diseases; however, their pharmacological effects, especially on cancer cells, differ from those of GBT.
Furthermore, the molecular mechanisms behind effects of GBT remain unclear. In the present study, we explored
the mechanism of chemopreventive/chemotherapeutic efficacy of GBT against human squamous cell carcinoma
without cytotoxicity in normal cells and proved the efficacy of GBT through performing in vivo xenograft assay.
Methods: For analysis of the constituents of GBT, high performance liquid chromatography (HPLC)-DAD system
was performed. To detect the anticancer effect of GBT, cell viability assay, caspase activity assay, cell cycle analysis,
DNA fragmentation analysis, and Western blot analysis were performed in A431 cells. In addition, the inhibitory
effect of tumor growth by GBT was evaluated in athymic nude mice inoculated with A431 cells.
Results: GBT showed cytotoxic activity against three different squamous cell carcinoma, especially on A431 cells.
GBT induced the apoptosis through activating the caspase-8 in A431 cells. Inhibition of A431 cell growth by GBT
was caused by G1-phase arrest through regulating proteins associated with cell cycle progression, such as cyclin
D1, p21, and p27. Furthermore, GBT regulated the activation of mitogen-activated protein kinases (MAPKs) including
extracellular signal-regulated kinase (ERK), p38 and c-Jun NH2-terminal kinase (JNK), and activated p53, a tumor
suppressor protein. In MAPKs inhibitor study, inhibitors respectively blocked GBT-induced cell viability, indicating
that MAPKs signals play critical role in cell death caused by GBT. In vivo xenografts, daily oral administration of
600 mg/kg GBT efficiently suppressed the tumorigenic growth of A431 cells without side effects such as loss of
body weight and change of toxicological parameters compared to vehicle.
Conclusions: We first elucidate that GBT stimulates the apoptotic signaling pathway and suppresses the
proliferation of A431 cells via regulating MAPKs signaling pathway. Furthermore, GBT significantly inhibits tumor
growth of A431 cells without causing systemic toxicity. Based on our study, GBT could be useful in the
management of skin cancer as chemoprevention and chemotherapy remedy.
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Table 1 Composition of the Guibitang (GBT) preparation
Scientific name Part used Amount used (g)
Angelica gigas Nakai Radix 4
Dimocarpus longan Fructus 4
Zizyphus jujuba Miller Seed 4
Polygala tenuifolia Rhizoma 4
Panax ginseng Radix 4
Astragalus membranaceus Radix 4
Atractylodes ovata Rhizoma 4
Poria cocos Radix 4
Zingiber officinale Rosc. Rhizoma 2.48
Inula helenium L. Radix 2
Zizyphus jujuba Miller Fructus 2
Glycyrrhiza glabra Fisch Radix 1.2
Total amount 44.69
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Basal cell carcinoma (BCC) and squamous cell carcin-
oma (SCC) are commonly referred to as non-melanoma
skin cancers [1,2]. BCC is a slow-growing cancer that
does not usually metastasize. Similarly, SCC is frequently
localized without evidence of blood-born metastasis,
making direct treatment of the tumor straightforward.
However, SCC is the sixth most common cancer world-
wide, and its incidence has increased dramatically at
multiple sites in the body, including the head and neck,
cervix, and lung [3,4]. Accordingly, it is necessary to de-
velop novel effective chemopreventive agents to inhibit
the development of SCC.
Guibitang (GBT), known as ‘Kihi-to’ in Japan and ‘Gui-
Pi-Tang’ in China, is a traditional medicine and herbal
formula that has been used for several hundred years,
predominantly to treat insomnia, amnesia, palpitations,
anxiety, fatigue, poor appetite, and depression [5]. Recent
studies have reported the specific bioactivities of GBT,
which include immune regulation [6], antioxidant effects
[7], and protective effect of the gastric mucosa [8]. GBT
is an aqueous polyherbal formulation that contains 12
herbs: Angelica gigas Nakai, Dimocarpus longan, Zizy-
phus jujuba Miller (seed), Polygala tenuifolia, Panax
ginseng, Astragalus membranaceus, Atractylodes ovate,
Poria cocos, Inula helenium, Glycyrrhiza glabra, Zingiber
officinale, and Zizyphus jujuba Miller (Fructus). GBT also
regulates chronic fatigue syndrome-associated cytokine
production, whereas the addition of Gardenia jasmi-
noides, Paeonia suffruticosa, and Bupleurum falcatum to
GBT improves palliative care in patients undergoing
chemotherapy for ovarian cancer [9]. Although it has
been shown that adding several herbs to GBT results in
anti-cancer effects against gynecological or lung cancer,
the molecular mechanisms behind these effect of GBT
remain unclear. Tumorigenesis is caused by unregulated
growth of cells resulting from DNA damage, mutations
of functional genes, dysregulation of the cell cycle, and
loss of apoptotic function [10]. Therefore, regulating the
induction of apoptosis by modulating cell growth and
survival-related signaling pathways is a common and
major target for cancer therapies [11]. Among several
signaling pathways in cancer cells, mitogen-activated
protein kinase (MAPK) signals including extracellular
signal-regulated kinases (ERK), p38 kinases, and c-Jun N-
terminal kinases (JNK), take an important role in cell
death and survival [12]. The regulation of ERK activation
is induced by conditions of stress such as some agents
and oxidant injury, which plays a major role in regulating
cell growth and differentiation [13]. JNK and p38 are ac-
tivated in response to several stress signals including
tumor necrosis factor and hyperosmotic condition, which
is associated with induction of apoptosis [14]. In the
present study, we evaluated whether GBT shows the anti-cancer effect in A431 human squamous carcinoma cells,
which demonstrated that GBT induces apoptosis of can-
cer cells specifically, as an inhibition of the cell growth
via regulating MAPK signaling pathway in A431 cells.Methods
Cell culture
Various human cancer cell lines, obtained from the
Korean Cell Line Bank (KCLB, Seoul, Korea) and
American Type Culture Collection (ATCC, Rockville,
MD), were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) and RPMI-1640 (Lonza, Walkers-
ville, MD) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT). Primary hepatic cells ob-
tained from mice were grown in Williams E Medium
(GIBCO, Gaithersburg, MD) supplemented with 10%
FBS. All media contained 100 U/mL penicillin G and
100 μg/mL streptomycin (GIBCO). Cells were incubated
in a humidified 5% CO2 atmosphere at 37°C.Herb materials and preparation of GBT
GBT was composed of 12 medicinal herbs; their constitu-
tion ratio is shown in Table 1. The 12 herbs were pur-
chased from the Korea Medicine Herbs Association
(Yeongcheon, Korea). The herbal mixture was extracted
by heating in water of 8-10 fold the herb weight for 3 h at
115°C on Cosmos–600 extractor (Incheon, Korea). After
boiling, the extract was filtered out using standard testing
sieves (pore size 150 μm, Retsch, Germany) and prepared
in the form of powder by freeze-drying. 50 mg of GBT
powder was dissolved in 1 mL of distilled water, passed
through a 0.22 μm filter, and stored at −20°C before use.
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Standardization of herbal extracts was performed by high-
performance liquid chromatography (HPLC) fingerprint-
ing with chemical standards purchased from Wako Pure
Chemical Industries (Japan; liquiritin), the Korea Food &
Drug Administration (KFDA; 6-gingerol), Elcom Science
(Korea; decursinol, decursin, and decursinol angelate),
Chengdu Must Bio-Technology (China; onjisaponin B),
and Sigma-Aldrich (USA; spinosin, vanilylacetone, noda-
kenin, nodakenetin, liquiritigenin, ginsenoside Rg1 and
Rb1, calycosin, jujuboside A, formononetin, atractyleno-
lide I, II and III, costunolide, and pachymic acid). Standard
solutions were prepared by dissolving each marker com-
ponent in 100% methanol at 1 mg/mL. GBT powder was
weighed accurately and dissolved in 60% methanol at
50 mg/mL for analysis. The HPLC-DAD system used
(Hitachi Co., Japan) consisted of a pump (L-2130), auto-
sampler (L-2200), column oven (L-2350), and diode array
UV/VIS detector (L-2455). Output signals from the de-
tector were recorded using EZChrom Elite software from
Hitachi. For sample analysis, a HECTOR-A-C18 column
(5 μm, 4.6 × 250 mm, RS Tech, Korea) was used and the
UV wavelengths were 203 and 254 nm. The mobile phaseFigure 1 HPLC fingerprints of individual herbs and GBT extracts. (A) G
officinale Rosc. (D) Angelica gigas Nakai. (E) Panax ginseng. (F) Astragalus m
helenium L. (J) Poria cocos. (K) GBT (203 nm). (L) GBT (254 nm).used was water (A) and acetonitrile (B) at a flow rate of
1.0 mL/min and the column temperature was maintained
at 40°C. The elution conditions applied during the analysis
were as follows: 0–10 min, isocratic 1% B; 10–70 min,
linear gradient 1–50% B; 70–80 min, linear gradient
50–100% B; and 80–90 min, isocratic 100% B. The sample
injection volume was 10 μL. Figure 1 shows the HPLC fin-
gerprints of GBT extracts (Table 2).
Cell viability assay
Cells (4 × 103 or 5 × 103 per well) were inoculated in a
96-well plate and treated with GBT for 24 or 48 h.
After incubation, cell viability was analyzed by 3-[4, 5-
dimethylthiazol-2-ly]-2, 5-diphenyl-tetrazolium bromide
(MTT) assay as described previously [15]. For growth
analysis, cells were seeded at a density of 1 × 105/mL and
treated with GBT for 1, 2, or 3 days. The cells were
counted and the doubling time was calculated using an
online tool (www.doubling-time.com/compute.php).
Cell cycle analysis
Cells were seeded at a density of 1 × 105/mL and treated
with GBT for 12 or 24 h. The propidium iodide (PI;lycyrrhiza glabra Fisch. (B) Zizyphus jujuba Miller (seed). (C) Zingiber
embranaceus. (G) Polygala tenuifolia. (H) Atractylodes ovata. (I) Inula




Compound name Classification* tR (min) Wavelength
(nm)
1 Liquiritin 12 43.25 254
2 Spinosin 3 43.71 203
3 Vanilylacetone 9 44.70 203
4 Nodakenin 1 44.99 203
5 Nodakenetin 1 51.18 203
6 Decursinol 1 52.55 203
7 Liquiritigenin 12 52.75 254
8 Ginsenoside Rg1 5 51.37 203
9 Calycosin 6 54.40 254
10 Formononetin 6 61.26 254
11 Jujuboside A 11 64.18 203
12 Ginsenoside Rb1 5 65.16 203
13 Onjisaponin B 4 67.59 203
14 6-gingerol 9 69.00 203
15 Atractylenolide I 7 70.75 254
16 Costunolide 10 78.16 203
17 Atractylenolide II 7 78.84 203
18 Decursin + Decursinol
angelate
1 79.35 203
19 Atractylenolide III 7 81.67 254
20 Pachymic acid 8 86.36 203
*1, Angelica gigas Nakai; 2, Dimocarpus longan (not detected); 3, Zizyphus
jujuba Miller (seed); 4, Polygala tenuifolia; 5, Panax ginseng; 6, Astragalus
membranaceus; 7, Atractylodes ovate; 8, Poria cocos; 9, Zingiber officinale Rosc.;
10, Inula helenium L.; 11, Zizyphus jujuba Miller (fructus); 12, Glycyrrhiza
glabra Fisch.
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analysis were performed as described previously [15].
DNA contents of the stained cells were analyzed by
FACS Calibur flow cytometry using Cell Quest software
(Becton–Dickinson, Franklin Lakes, NJ).
Caspase activity assay
To determine caspase-3/7 activity, cells were seeded at a
density of 1 × 104/well in a 96-well plate and treated with
GBT for 24 h. Caspase activity was measured in tripli-
cate by using a Caspase-Glo 3/7 assay kit (Promega,
Madison, WI) according to the manufacturer’s instruc-
tions. Culture medium was used as a blank control and
luminescence was measured using an MLX microtiter
luminometer (Dynex Technologies Inc., Chantilly, VA).
DNA fragmentation analysis
To investigate the apoptotic effect of GBT, we assessed
oligonucleosomal DNA fragmentation by agarose gel
electrophoresis. Cells were harvested at 12 and 24 h after
treatment. Genomic DNA was prepared from harvestedcells using a Genomic DNA Purification Kit (Promega,
Madison, WI) according to the manufacturer’s instruc-
tions. It was then subjected to electrophoresis on a
1.5% agarose gel impregnated with ethidium bromide
reagent (Sigma-Aldrich, St. Louis, MO) to detect ladder
formation.
Western blot analysis
The cell lysates treated with GBT for western blot analysis
were prepared as described previously [15]. The same
amount of protein for each sample was electrophoresed
and transferred onto a polyvinylidene difluoride (PVDF)
membrane (Millipore, Billerica, MA). Proteins were de-
tected using primary antibodies specific for cyclin D1, cyc-
lin B1, p21, p27, caspase-3, caspase-8, caspase-9, Bid, Bax,
Bcl-2, PARP, ERK, phospho-ERK, p38, phospho-p38, JNK,
phospho-JNK, p53, GAPDH, and β-actin, all of which
were obtained from Cell Signal Technology. This was
followed by incubation with HRP-conjugated secondary
antibodies for 1 h at room temperature. The specific pro-
tein was detected using the enhanced chemiluminescence
imaging system (CoreBio, Seoul, Korea).
Animals and tumor xenografts
Female mice (Athymic nu/nu, 8 weeks, 25–29 g; NARA
Bio, Seoul, Korea) were acclimated under conditions of
constant temperature (24 ± 1°C) and humidity (55 ± 15%)
with 12 h light/dark cycle for 1 week. Mice were injected
subcutaneously with 3 × 106 A431 cells/100 μL harvested
and suspended in DMEM medium without FBS. Mice
with palpable tumors were divided into two groups for
study, and group 1 (vehicle, n=5) mice received the injec-
tion of physiological saline (Choongwae Normal Saline
Inj., Korea), whereas group 2 (GBT, n=5) orally received
GBT. The administrated amount of GBT for human
adults with an average body weight of 60 Kg is approxi-
mately 12~36 g/day and the yield of powdered extraction
is approximately 30% (wt/wt). Based on this estimation
data, GBT at the doses of 600 mg/day/Kg of body weight
was orally administered to mice for 14 days. GBT treat-
ment was started at day 3 following the tumor cell inocu-
lation. Tumor volume was monitored using electronic
caliper on every alternate day and tumor volume was
calculated using following formula: tumor volume =
length × width × width/2. The experiment was termi-
nated at the end of 15 days when the vehicle-treated ani-
mals had large tumors, which was sacrified by obtaining
blood from abdominal vein. For determining the toxicity
of GBT, chemical analysis of serums obtained from mice
was determined using an Auto Biochemistry Analyzer
(XL-200, Erba Diagnostics, Mannheim, Germany) and
complete blood cell count (CBC) from mice was analyzed
using a ADVIA 2120i Hematology System (Siemens
Healthcare, Camberley, UK). The animal experimental
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Medicine Care and Use Committee with a reference
number of #12-094 and #13-030, and performed in ac-
cordance with the Korea Institute of Oriental Medicine
Care Committee Guide lines.
Statistical analysis
Data are presented as means ± SD. Student’s t-test was
employed to assess the statistical significance of differ-
ences between the control and GBT-treated groups.
Values of p <0.05 and <0.01 were considered to indicate
statistical significance.
Results
GBT decreases cell viability in A431 human squamous
carcinoma cells
Six different human cancer cell lines (A431 [squamous],
AGS [stomach], HeLa [cervical], Caki-1 [kidney], SK-
Hep-1 [liver], and HCT116 [colon]) were treated with
500 μg/mL GBT for 48 h, and cell viability was assessed
by an MTT assay. Although most cell lines were un-
affected, the viability of A431 cells was inhibited >35%
by treatment with GBT (Figure 2A). Therefore, subse-
quent tests focused on A431 cells. To further define the
inhibitory action of GBT on SCCs, the suppression of
cell growth by GBT on three different SCC lines
(SCC12, SCC13, and A431) was evaluated. As shown in
Figure 2B, treatment with 500 and 1000 μg/mL GBT for
48 h reduced the viability of A431 cells by 35% and 52%,Figure 2 Anti-proliferative effect of GBT on human cancer cells. Cell v
percentages of viable cells compared to untreated cells (vehicle). Data show
(A) Inhibition of cell viability by GBT in several human cancer cell lines for
squamous carcinoma cell lines: A431, SCC12, and SCC13 for 48 h. (C) Effect
respectively. (D) Comparison of GBT-induced cytotoxicity between A431 ce
time-dependent manner.respectively. Treatment of SCC13 cells with 1000 μg/mL
GBT also inhibited the cell growth by ~30% although
these effects were not as potent as those observed in
A431 cells. In contrast, the viability of SCC12 cells was
not affected significantly by GBT. The potential cyto-
toxic effect of GBT on normal cells was assessed using
normal human HaCaT keratinocytes and mouse primary
liver cells. HaCaT cells were unaffected by GBT under
the same conditions that were cytotoxic to A431 cells
(Figure 2C). In addition, no cytotoxic effects on primary
liver cells were observed by treatment with 500 μg/mL
or 1000 μg/mL GBT. Instead, GBT weakly increased the
viability of liver primary cells in a dose- and time-
dependent manner (Figure 2D). These results suggest
that GBT has cancer-specific cytotoxic effect on A431
cells, without affecting normal cells.
GBT causes cell cycle arrest in G1 and increases the sub-
G1 population in A431 cells
A431 cells were treated with 500 and 1000 μg/mL GBT
for 12 or 24 h, and cell cycle progression was assessed.
Cells were stained with PI, and the percentage of cells at
each stage of the cell cycle was quantified using flow
cytometry. As shown in Figure 3A, GBT increased the
number of cells in the sub-G1 peak in a time- and dose-
dependent manner. After 24 h treatment with 500 and
1000 μg/mL GBT, 8.64% and 9.27% of cells had accu-
mulated in the sub-G1 phase, respectively, which repre-
sented up to a nine-fold increase compared to untreatediability was determined by MTT assay. The results are expressed as
the means ± SD of two independent triplicate experiments.
48 h. (B) Comparison of the effects of GBT on the viability of three
of GBT on the growth of A431 and HaCaT cells for 24 and 48 h,
lls and mouse primary liver cells (as a normal cells) in a dose- and
Figure 3 Effect of GBT on cell cycle progression in A431 cells. (A) Analysis of cell cycle progression. (B) Expression of cell cycle regulatory
proteins in GBT-treated cells for 24 h. Band intensity compared to untreated cells was calculated using ImageJ after normalization to β-actin
expression. The data represent two independent experiments. (C) The inhibition of cell growth by GBT for 3 days at concentrations without cell
death by GBT. Growth inhibition was assessed by counting trypan blue-excluding cells. The data represent the mean of two independent
triplicate experiments; the error bars show the standard deviation.
Yim et al. BMC Complementary and Alternative Medicine 2014, 14:344 Page 6 of 12
http://www.biomedcentral.com/1472-6882/14/344cells (CTL). In addition, 56.09% and 52.75% of cells
treated with 500 and 1000 μg/mL GBT accumulated in
G1 after 12 h, and remained comparable after 24 h.
Under the same conditions, the accumulation of cells in
S and G2/M phases were decreased by GBT compared
to CTL.
Based on these data, we investigated whether the ex-
pressions of cell cycle-regulating proteins are affected by
treatment with GBT. As shown in Figure 3B, treatment
with GBT altered the expression of proteins associated
with G1 phase progression. Specifically, the expression
of p21 and p27 was increased, whereas cyclin D1 levels
were reduced. In contrast, levels of cyclin B1, which
regulates the G2/M phase, was unaffected by GBT. The
results shown in Figure 3C confirm that the anti-
proliferative effects of GBT are due to the induction of
G1 arrest. Proliferation of A431 cells was inhibited after
24 h treatment with GBT, and the number of cells was
reduced two-fold by GBT compared to controls after
72 h. These data indicate that induction of G1 cell cycle
arrest by GBT hinders cell growth, which is related to
cell death in A431 cells.GBT-stimulated activation of pro-apoptotic proteins and
DNA fragmentation is attributable to the induction of
apoptosis in A431 cells
To assess whether GBT-induced cytotoxicity may be
related to apoptosis, we assessed DNA fragmentation
using gel electrophoresis (Figure 4A). An increase in the
amount of fragmented oligonucleosomal-length DNA
was detected after 24 h treatment with 500 μg/mL GBT,
but not at 12 h. To confirm these observations, the acti-
vation of caspase-3/-7, a key apoptotic mediator, was an-
alyzed in A431 cells treated with GBT for 24 h. As
expected, GBT increased caspase-3/-7 activity signifi-
cantly in a dose-dependent manner (Figure 4B). Next,
Western blotting revealed that procaspase-3 and -8,
but not -9, were cleaved to their active form after ex-
posure to GBT. Furthermore, GBT induced the cleavage
of PARP, a substrate of active caspase-3, in a dose-
dependent manner. In contrast, no Bid truncation was
detected and the expression of Bax was unaffected by
GBT despite the decrease of Bcl-2 levels (Figure 4C). To
confirm that the apoptosis induced by GBT requires
the activation of caspases, A431 cells were exposed to
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(Z-VAD), and caspase-3, -8, and -9 inhibitors (Z-DEVD,
Z-IETD, and Z-LEHD, respectively) for 30 min before
treatment with 500 μg/mL GBT. As shown in Figure 3D,
all caspase inhibitors inhibited the anti-proliferative ef-
fects of GBT, particularly Z-VAD and Z-DEVD. Taken
together, these results suggest that GBT-induced apop-
tosis in A431 cells requires the activation of caspases.
GBT regulates the phosphorylation of cell proliferation-
related proteins including MAPK cascades and p53 in
A431 cells
To investigate the relationship between the activation of
MAPKs and the inhibition of cancer cell proliferation,
we analyzed the levels of total and phosphorylatedFigure 4 Induction of apoptosis in A431 cells by GBT. (A) The observat
assay for 12 and 24 h, respectively. (B) Activation of caspase-3 in GBT-induc
experiments. *P<0.05 and **P<0.01 versus untreated control cells. (C) The e
for 24 h. Band intensity compared to untreated cells was calculated using I
two independent experiments. (D) The investigation of apoptotic effect of
with the caspase inhibitors Z-VAD-fmk (general), Z-DEVD-fmk (caspase-3), Z-
of 10 μM) for 30 min. Cell viability was determined by MTT assay, and the re
experiments. **P<0.01 versus untreated control cells; #P<0.05 and ##P<0.01 vMAPKs by Western blotting after GBT treatment. The
levels of p-p38 and p-ERK were upregulated after
15 min treatment with 500 μg/mL GBT, and the activa-
tion was sustained for 24 h (Figure 5A). In contrast, the
phosphorylation of JNK was upregulated transiently by
30 min exposure to GBT, but then dropped sharply by
24 h. The levels of p53 phosphorylated on Ser15 (p53-
Ser15P) were increased after 6 h treatment with GBT,
and expression remained elevated until 24 h. To further
investigate the regulation of these signaling pathway by
GBT, A431 cells were pretreated with MAPK inhibitors,
including PD98059 (which inhibits ERK1/2), SB203580
(p38), and SP600125 (JNK) for 30 min, followed by
treatment with 500 μg/mL GBT for 48 h (Figure 5B).
Each inhibitor abrogated the anti-proliferative effects ofion of DNA laddering induced by GBT using the DNA fragmentation
ed apoptosis for 24 h. Results are representative of three independent
ffect of GBT on the expression of pro-apoptotic proteins in A431 cells
mageJ after normalization to β-actin expression. The data represent
GBT for 24 h using the caspases inhibitor study. Cells were pretreated
IETD-fmk (caspase-8), and Z-LEHD-fmk (caspase-9) (all at a concentration
sults are shown as the means ± SD of two independent triplicate
ersus cells treated with GBT only.
Figure 5 Identification of the relationship between MAPK activation and the anti-proliferative effect of GBT on A431 cells. (A) The
activation of MAPKs and p53- Ser15P induced by GBT for the indicated times (0.25, 0.5, 1, 6, 12, and 24 h). Band intensity compared to untreated
cells was calculated using ImageJ after normalization to GAPDH expression. The data represent two independent experiments. (B) The investigation
of anti-proliferative effect of GBT for 48 h using the MAPK cascade inhibitors PD98059 (10 μM), SB203580 (10 μM), and SP600125 (10 μM). Cell
morphology was observed under a phase-contrast microscope and cell viability was determined by MTT assay. The results show the means ± SD of
two independent triplicate experiments. **P<0.01 versus untreated control cells; and #P<0.05 and ##P<0.01 versus cells treated with GBT only.
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reduced cell death by 30% compared to GBT alone. Taken
together, these data suggest that GBT has anti-proliferative
effects on A431 cells by modulating MAPK signaling path-
ways, resulting in the induction of apoptosis.
GBT administration inhibits tumorigenic growth of A431
cells in vivo
To confirm these observations, we assessed the inhibitory
effects of GBT on tumor growth in athymic nude mice
injected with A431 cells. Mice harboring xenograft tu-
mors were treated orally with either vehicle (control) or
600 mg/Kg/day GBT. Importantly, arrest in the growth
of xenografts treated with GBT was observed after 7 days
of treatment, followed by a significant reduction in tumor
size at the end of experiment on day 15. In addition,
GBT did not cause any adverse side effects such as loss
of body weight or skin ulcers (Figure 6A, B). Treatment
with GBT resulted a 52% inhibition of tumor growth
compared to vehicle (Figure 6C, D). There were no sig-
nificant differences in serological parameters among the
three groups (Table 3). The ratios of GOT/GPT and
BUN/CRE were not significantly changed in the GBT-treated group compared to control. In addition, the lac-
tate dehydrogenase (LDH) ratio was decreased by ~23%
by GBT treatment, suggesting that GBT did not cause
hepatic or renal damage. The hematological parameters
of the GBT-treated group were similar to the vehicle
group (Table 4). The number of red blood cells (RBCs)
and hemoglobin levels, an indicator of RBC count and
anemia, was unchanged by GBT. White blood cell (WBC)
counts and other parameters were also within the normal
ranges. Therefore, these results provide strong evidence
for the anti-cancer effects of GBT in vivo.
Discussion
Traditional medicine in Asian countries commonly com-
bines herbs to create multi-herbal formulas for treating
target diseases, and the use of these formulas has been
verified scientifically as complementary or alternative
cancer therapies [16]. Especially, advanced diseases in-
cluding cancer require the multi-targeting treatment in
cellular signaling pathways, herbal formulas may achieve
better therapeutic efficacy according to the synergy than
that of a single herb [17]. However, multi-herbal formulas
must be pre-clinically evaluated to accurately compare
Figure 6 In vivo anti-tumor activity of GBT. The A431 cells were injected into anthymic nude mice and treated daily with either vehicle or
600 mg/Kg for 14 days, which was terminated at the end of 15 days. The results show the significant reduction of tumors by GBT. (A) Tumor
growth inhibition by GBT. (B) Changes in body weight during the administration of GBT. (C, D) Comparision of anti-tumor activity between
vehicle and GBT according the representive tumor images and the measurement of tumor weight. Data shown are mean ± SD, *P < 0.05
versus vehicle.
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[18]. In the present study, 14 standards in 12 constituent
herbals from GBT were identified in the GBT samples. A
previous study has reported that decursin, decursinol,
and decursinol angelate from A. gigas Nakai indicate the
anti-cancer effects in colon and breast carcinoma cells
via inhibition of proliferation and induction of apoptosis
[19,20]. Ginsenoside Rg1 and Rb1 from P. ginseng have
anti-proliferative effect in colon cancer via cell cycle
arrest and apoptosis induction [21]. A recent study has
reported that vanilylacetone from Z. offcinale Rosc. has
anti-carcinogenic properties against colon cancer, and 6-Table 3 Chemical analysis of serums obtained from mice adm
Treat. GOT (IU/L) GPT (IU/L) ALP (IU/L)
Vehicle 54.0 ± 3.5 28 ± 0.0 48.0 ± 22.3
GBT 41.3 ± 4.6 26 ± 0.0 30.7 ± 21.9
Each group of mice (n=5) was treated orally with 600 mg/Kg GBT for 14 days. The l
cytotoxic effects of GBT. Data are expressed as mean ± S.D.
GOT, glutamic oxaloacetic transaminase; GBT, glutamic puruvic transaminase; ALP, a
CRE, creatinine.gingerol has apoptotic effect against breast and prostate
carcinoma cells via modulation of STAT3 and MAPK sig-
naling pathway [22,23]. In addition, formononetin from
A. membranaceus induces apoptosis in prostate cancer
cells via enhancing the Bax/Bcl-2 ratios and regulating
the p38 phosphorylation [24]. Other reports have demon-
strated that sesquiterpenoids from A. ovate, such as
atractylenolide I, II, and III, exists anti-tumor effect in
lung carcinoma cells via caspase-dependent apoptosis
pathway [25,26]. These reports suggest that the anti-
cancer effect of GBT might be related to these active
components. In this study, GBT induced apoptosis ininistrated with 600 mg/Kg of GBT
LDH (IU/L) UREA (mg/dL) CRE (mg/dL)
420.0 ± 65.8 27.9 ± 7.6 1.0 ± 0.0
319.3 ± 94.7 27.5 ± 0.2 1.0 ± 0.0
evels of GOT, GPT, ALP, LDH, BUN, and CRE were analyzed to confirm the
lkaline phosphatase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen;
Table 4 Hematological analysis of bloods obtained from
mice administrated with 600 mg/Kg of GBT
Parameters Vehicle GBT
WBCP (x103 cells/μL) 4.48 ± 1.22 4.02 ± 1.19
WBCB (x103 cells/μL) 4.53 ± 1.15 4.10 ± 1.24
RBC (x106 cells/μL) 8.74 ± 0.26 8.99 ± 0.48
Means HGB (g/dL) 13.8 ± 0.06 14.0 ± 1.11
HCT (%) 47.8 ± 1.40 49.1 ± 1.81
MCV (fL) 54.7 ± 0.40 54.6 ± 0.86
MCH (pg) 15.8 ± 0.40 15.6 ± 0.40
MCHC (g/dL) 28.8 ± 0.74 28.6 ± 1.15
PLT (x105 cells/μL) 11.4 ± 7.35 11.3 ± 11.17
% NEUT 21.7 ± 1.63 26.0 ± 4.76
% LYM 71.7 ± 1.81 67.2 ± 5.78
% MONO 1.40 ± 0.35 1.30 ± 0.44
Each group of mice (n=5) was treated orally with 600 mg/Kg GBT for 14 days,
and leucocytes were analyzed. Data are expressed as mean ± S.D.
WBCP, white blood cell count peroxidase method; WBCB, white blood cell
count basophile method; RBC, red blood cell count; HGB, hemoglobin; HCT,
hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular
hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT,
platelet; NEUT, neutrophil; LYM, lymphocyte; MONO, monocyte.
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cancer cell proliferation without affecting the viability of
HaCaT keratinocytes or mouse primary hepatocytes.
Based on these preliminary observations, we assessed the
molecular mechanism of the anti-cancer effects of GBT
on A431 cells. GBT increased the formation of fragmen-
ted DNA ladders as well as other apoptotic features such
as chromatin condensation. In Western blot analysis,
GBT affected the expression of pro- and anti-apoptotic
proteins, espectially, GBT enhanced the activation of cas-
pases in A431 cells. Caspases are a family of cysteine pro-
teases that, when inactive, exist in proenzyme form.
Upon the induction of apoptosis, they become activation
via a self-amplifying cascade [27]. The activation of initi-
ator caspases such as caspases-8, -9, and -10 by pro-
apoptotic signals leads to downstream activation of the
effector caspases-3, -6, and -7. The caspase cascades are
divided into two major pathways: an extrinsic pathway
initiated by ligand-mediated activation of cell surface
death receptors, and an intrinsic pathway activated by
intracellular signals from the mitochondria [28]. In the
present study, the activation of caspase-8 and -3 and the
cleavage of PARP correlated precisely with the DNA frag-
mented ladder after treatment with GBT, whereas the
levels of procaspase-9 decreased slightly, without the
appearance of the cleaved form. The Bcl-2 family of pro-
teins, including Bid, Bcl-2, and Bax, regulate the activa-
tion of caspase-9 [29]. In our study, GBT-stimulated
active caspase-8 did not increase the levels of truncated
Bid, although total Bid levels were reduced. Our data sug-
gest that the activation of caspase-8 by GBT results inthe direct activation of caspase-3, which is typical of the
extrinsic apoptotic pathway, suggesting that GBT acti-
vates extrinsic apoptosis to have anti-cancer effects on
A431 cells. We also found that GBT stimulated the phos-
phorylation of MAPKs and p53, signaling pathways that
are required for cell growth and tumorigenesis. MAPK
cascades including ERK, p38, and JNK, regulate cellular
processes including proliferation, differentiation, and
apoptosis [30]. Especially, Pharmacological modulation of
MAPK singals has been confirmed in previous studies to
influence the apoptotic response to anti-tumor agents.
For example, ERK activation by treatment with cisplatin
plays a key role in mediating cisplatin-induced apoptosis
of HeLa human cervical carcinoma cells, which induces
caspase activation [31]. Another example is represent
that the role of MAPK and p53 pathways in cancer cells
is associated with anti-cancer effect of chemotherapeutic
agents such as vinblastine, doxorubicin and etoposide
[32]. In the present study, we identified that GBT treat-
ment activated the ERK, p38, and JNK signals, which
retained during apoptosis of A431 cells. In addition, in-
hibition of MAPK signaling by the specific inhibitors
(PD98059, ERK inhibitor; SB203580, p38 inhibitor;
SP600125, JNK inhibitor) protected cells from the cyto-
toxic effects of GBT, suggesting that activation of MAPK
cascades play a opposite role in A431 cell proliferation.
MAPKs are activated upon exposure to stress, leading to
the phosphorylation and activation of p53. The activation
of MAPKs can activate p53 to phosphorylation form at
various serine residues, resulting in p53-mediated cellular
responses such as DNA repair, cell cycle arrest, and the
induction of apoptosis [33]. The phosphorylation of p53
at serine 15 (p53-Ser15P) by p38 or ERK results in the in-
duction of apoptosis in cancer cells [34,35]. In contrast,
activated JNK plays a direct role in the phosphorylation
of p53 at serine 20, leading to the activation and
stabilization of p53. In cell cycle progression relevant to
cell proliferation, furthermore, the activation of p53
causes cell cycle arrest in the G1 phase, which mediated
by p21 and p27, inhibitors of cyclin/CDK complexes
[36,37]. In present study, the activation of ERK, p38, and
JNK by GBT corresponded with increase of p53-Ser15P
expression in A431 cells, which caused the up-regulation
of p21 and p27 expressions during GBT-induced apop-
tosis. Taken together, these results strongly suggest that
activation of MAPK cascades by GBT induces phosphor-
ylation of p53, which results in induction of apoptosis for
A431 cells.
Based on results demonstrated in A431 cells in vitro,
we performed xenograft assay in athymic nude mice. In
the evaluation of inhibitory effect of GBT against tumor
growth after 15 days of daily oral administration, GBT
significantly suppresses tumor growth of subcutaneously
injected A431 cells without side effects such as body
Yim et al. BMC Complementary and Alternative Medicine 2014, 14:344 Page 11 of 12
http://www.biomedcentral.com/1472-6882/14/344weight loss, organ abnormalities, and hematological/sero-
logical parameter changes. Therefore, GBT has a signifi-
cant anti-tumorigenic effect in vivo.
Conclusions
This study assessd the efficacy of GBT anti-cancer effect
in vitro and vivo. Our results strongly demonstrated that
GBT induced apoptosis by regulating the activity of
MAPK cascades and p53 in A431 cells. Further, oral ad-
ministration of GBT obviously inhibited in vivo tumor
cell growth of A431 cells without causing systemic tox-
icity. Resultingly, we suggest that GBT has potential as a
herbal medicine for controlling malignant tumor growth.
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